What happened to the oncology assets (BNC101 &105)?
CEO/MD report Nov 2017:
"We are working diligently on additional strategic partnership opportunities, including the monetisationof BNC101 and BNC105, to achieve our corporate objectives."
There was a lot of R&D sunk into those candidates. What are they worth today? What's being done to "monetise" them?
(crickets chirping...)